Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Enterprise Value (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Enterprise Value readings, the most recent being -$13.6 million for Q4 2023.

  • On a quarterly basis, Enterprise Value fell 74.63% to -$13.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$13.6 million, a 74.63% decrease, with the full-year FY2023 number at -$13.6 million, down 74.63% from a year prior.
  • Enterprise Value hit -$13.6 million in Q4 2023 for Elicio Therapeutics, up from -$16.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$598000.0 in Q2 2022 to a low of -$130.5 million in Q1 2021.
  • Median Enterprise Value over the past 4 years was -$21.7 million (2023), compared with a mean of -$47.5 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 99.49% in 2022 and later tumbled 3525.75% in 2023.
  • Elicio Therapeutics' Enterprise Value stood at -$34.6 million in 2020, then crashed by 156.47% to -$88.8 million in 2021, then surged by 91.22% to -$7.8 million in 2022, then tumbled by 74.63% to -$13.6 million in 2023.
  • The last three reported values for Enterprise Value were -$13.6 million (Q4 2023), -$16.5 million (Q3 2023), and -$21.7 million (Q2 2023) per Business Quant data.